Immunome (NASDAQ:IMNM) Director Sells $2,259,000.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 100,000 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total value of $2,259,000.00. Following the transaction, the director directly owned 208,504 shares of the company’s stock, valued at $4,710,105.36. The trade was a 32.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Performance

Shares of Immunome stock opened at $23.61 on Friday. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The company has a market cap of $2.67 billion, a PE ratio of -9.92 and a beta of 2.07. The business has a 50-day simple moving average of $20.96 and a 200-day simple moving average of $21.80.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, sell-side analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Trading of Immunome

Several institutional investors have recently modified their holdings of IMNM. T. Rowe Price Investment Management Inc. lifted its position in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. Vanguard Group Inc. boosted its stake in Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after acquiring an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. State Street Corp grew its holdings in shares of Immunome by 37.9% during the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after purchasing an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research note on Friday, June 12th. Leerink Partners decreased their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Finally, Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Immunome presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.